TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05138003

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
Study: NCT06210633

Intervention type: OTHER
Intervention: medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.

Intervention type: OTHER
Intervention: medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
Study: NCT05632289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative therapy
Description: osteopathic manipulative therapy : manuel therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic manipulative therapy
Description: placebo of osteopathic treatment
Study: NCT04887558

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T Mental Health and NRT
Description: Smart-Treatment Mental Health App and Nicotine Replacement Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T Mental Health+ and NRT
Description: Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide + NRT
Description: NCI QuitGuide Treatment App and Nicotine Replacement Therapy
Study: NCT06280716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid
Study: NCT06004336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Given by vein (IV)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Given by vein (IV)
Study: NCT06117592

Intervention type: OTHER
Intervention: Education, training and assessment intervention
Description: Staff competence assessment documents for acute oncology knowledge and skills

Intervention type: OTHER
Intervention: Education, training and assessment intervention
Description: Staff competence assessment documents for acute oncology knowledge and skills
Study: NCT06187506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: 2.0 mg/kg, administered intravenously every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin Vaccine
Description: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
Study: NCT05319847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Skin Supplement - Fountain of Youth
Description: Skincare supplement
Study: NCT06210633

Intervention type: OTHER
Intervention: endovascular thrombectomy
Description: Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
Study: NCT05425576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101
Description: OT-101 in combination of pembrolizumab
Study: NCT04935736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal sealer : CORTISOMOL SP
Description: The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: root canal sealer : SEALITE REGULAR
Description: The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
Study: NCT04712175

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal sampling
Description: Swabs will be taken of nasopharyngeal samples for RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal sampling
Description: Swabs will be taken of nasopharyngeal samples for RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sampling
Description: A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sampling
Description: A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
Study: NCT05055908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Pembrolizumab
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Study: NCT05897424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-101
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein
Study: NCT06513468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group education session by DESMOND Program
Description: is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group education session by DESMOND Program
Description: is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
Study: NCT06640114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon CT
Description: Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin).
Study: NCT05311969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive evaluations and non cognitive evaluations
Description: Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory
Study: NCT04817982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Description: Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be added perineurally to an ulnar nerve block with bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic dexamethasone
Description: Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
Study: NCT05877105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle
Description: VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
Study: NCT05791331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surfactant administration following lung mechanics assessment in addition to clinical assessment
Description: Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant administration following clinical assessment
Description: Surfactant is administered following oxygenation-based criteria
Study: NCT05297838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Bike
Description: Stationary Bike while hand is submerged in ice bath

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Bike
Description: Stationary Bike while hand is submerged in ice bath

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Headset
Description: VR headset containing gameplay

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Headset
Description: VR headset containing gameplay

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Bath
Description: Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Bath
Description: Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
Study: NCT06063343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND145
Description: In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND145
Description: In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
Study: NCT05930470

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Magnetic Mitohormesis Therapy
Description: The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Mitohormesis Therapy
Description: The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
Study: NCT04490655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active somatosensory training
Description: Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor-based training
Description: Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
Study: NCT05481281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
Study: NCT05569941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-4334 Tablet
Description: ABI-4334 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-4334 Tablet
Description: ABI-4334 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-4334 Tablet
Description: ABI-4334 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-4334 Placebo
Description: Placebo to ABI-4334 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-4334 Placebo
Description: Placebo to ABI-4334 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-4334 Placebo
Description: Placebo to ABI-4334 Tablet
Study: NCT06195605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane-L
Description: Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
Study: NCT05926531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBTI online programe
Description: 20 MIN VR RELAX PROGRAME

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBTI online programe
Description: 20 MIN VR RELAX PROGRAME
Study: NCT04915300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apabetalone
Description: Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. (tablets) BID for 24 weeks treatment period.
Study: NCT05484167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natesto Nasal Product
Description: Nasal Gel used for 90 days then crossed over to placebo gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A nasal gel with no active ingredients
Study: NCT05352113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
Study: NCT05869409

Intervention type: BEHAVIORAL
Intervention: Physical activity and sedentary behavior education
Description: Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
Study: NCT05276453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMove Suit
Description: 12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal therapy
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
Study: NCT06122545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve Block
Description: Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Treatment
Description: Patients who will receive medical treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine or onabotulinum toxin A injection.
Description: bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
Study: NCT05391152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic assisted total knee replacement
Description: the study group used robotic-arm assisted total knee replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional total knee replacement
Description: the control group used traditional total knee replacement
Study: NCT06026306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session